Case 2 – Trabectedin as a maintenance therapy in a patient with recurrent ovarian cancer and BRCA1 germline mutation

Abstract

Treatment of patients with recurrent ovarian cancer (ROC) is complex. This case report describes the effects of a sequence of treatments in a BRCA1 mutation carrier with serous papillary poorly differentiated, platinumsensitive ROC. This consisted in primary surgery, adjuvant chemotherapy, secondary cytoreduction with Heated IntraPEritoneal Chemotherapy (HIPEC), 12 cycles of trabectedin in combination with pegylated liposomal doxorubicin (PLD) and 12 cycles of trabectedin alone, leading to complete radiological and biochemical response.